Moving from Copilot to Claude implies a deliberate platform choice: model capability, EU data sovereignty positioning, infrastructure flexibility. The window between license deployment and operational maturity is exactly when an organizing methodology compounds; once habits set on the new platform, they are expensive to reset.

Why it matters: justifies engaging now rather than after the platform is bedded in. If the transition is treated as a tool swap, we lose the leverage.

CZ · SK · PL · RO · IT are not five copies of one market. Online OTC sales rules differ. Telepharmacy frameworks differ. GDPR national supplements differ. Prescription validation flows differ.

Implication: any agent that touches the customer is either Custom Built per market or Custom Built once and inertia-blocked from going further. The methodology must encode this — not paper over it.

Pharmacy retail margin lives in OTC, cosmetics, private label cross-sell — not Rx (reimbursed at fixed margins by national payers). Customer-facing AI on digital platforms touches the actual margin engine.

Implication: Peter is on the critical path for Group economics. Increases leverage and raises the rigor bar.